Unlocking the Power of Ultrasensitive Bioanalysis

Unlocking the Power of Ultrasensitive Bioanalysis

🔬 How do you measure complex modality molecules at the lowest possible concentrations?

For modern therapies like antibody-drug conjugates (ADCs) and inhzlation drugs, precise bioanalysis at picogram levels is essential to ensure both efficacy and safety. At Resolian, we specialize in ultrasensitive assays that push the boundaries of detection using:

✅ Advanced sample preparation techniques to refine analyte extraction

✅ Optimized chromatography (including 2D-LC) for maximum separation and reduced noise

✅ Cutting-edge mass spectrometry for ultra-low detection limits

From chemical structure analysis to high-sensitivity LC-MS, our expert team ensures accurate quantification of even the most challenging analytes.

 

🎥 Watch the video interview here 👉

📖 Read the full article below to explore our approach in detail. 👇

Ultrasensitive Assays for Bioanalysis: Resolian’s Approach

For targeted and high potency therapies, ultrasensitive bioanalytical assays are essential to monitor low-concentration analytes accurately. In this article we explore the methods used by Resolian’s team, led by Executive Director of Bioanalysis Aihua Liu, we detail critical steps in assay development, including understanding chemical structures, optimizing sample preparation, chromatographic separation, coupled with mass spectrometry detection, allowing for precise measurement even at picogram levels.

The Importance of Ultrasensitive Assays in Modern Therapies

Therapies such as antibody-drug conjugates (ADCs) and inhalation drugs require ultrasensitive assays due to their low-dose delivery mechanisms and the high potency of active ingredients. These therapies, designed to minimize impact on healthy cells while delivering targeted effects, require exact quantification at trace levels to ensure both efficacy and safety.

Understanding the Chemical Structure

The process begins with an in-depth understanding of the target analyte’s chemical structure, which informs all subsequent steps. Knowing the structural details enables analysts to predict sensitivity, identify functional groups for sample preparation, and optimize LC-MS conditions. For instance, analytes with specific groups, like secondary amines e.g. Formoterol, can achieve picogram sensitivity through the use of low pH mobile phases to increase ionization efficiency.

Challenges Without Structural Information: Confidentiality concerns sometimes limit access to the analyte’s chemical structure. Even in the absence of that information, perhaps with only a molecular weight, our team can adapt their approach, typically employing a larger sample volume and a smaller reconstituted solvent volume, and also the large injection volume to proceed effectively. This approach then relies on an optimized sample preparation protocol.

Optimizing Sample Preparation: The AMOEBA Protocol

Sample preparation is crucial for minimizing matrix effects and enhancing analyte sensitivity. Resolian has implemented a standardized protocol known as AMOEBA, which streamlines method development through the systematic testing of techniques, including protein precipitation extraction (PPE), liquid-liquid extraction (LLE), supported liquid extraction (SLE), and solid-phase extraction (SPE). SPE is often necessary for ultrasensitive assays, allowing Resolian to effectively isolate analytes from interferences and achieve desired sensitivity levels.

Combined Techniques for Maximum Sensitivity: In cases requiring enhanced extraction, Resolian combines multiple methods, such as PPE+SPE or LLE+SPE, to refine analyte concentration. The systematic approach is efficient and eliminates the need to re-evaluate the sample prep protocol later.

Chromatographic Optimization for Efficient Separation

For known analyte structures, the column and mobile phase selection can be tailored to structural characteristics. When chemical structure details are lacking, Resolian uses a design-of-experiments (DoE) approach to screen column types (e.g., C4, C8, C18, phenol) and mobile phases, optimizing conditions rapidly. The company employs a pre-prepared set of columns and mobile phases to complete these screens in under a day.

Two-Dimensional Chromatography (2D-LC): For ultrasensitive assays, Resolian often utilizes two-dimensional chromatography, which enhances separation by using two columns with differing mechanisms. This technique lowers background noise and improves signal quality, essential for distinguishing low-level analytes from complex matrices.

Maximizing Detection Sensitivity Through Triple Quadrupole Mass Spectrometry

Triple quadrupole mass spectrometry (MS) is critical in achieving the detection sensitivity necessary for ultrasensitive assays. Resolian uses advanced instruments like the Sciex 7500 mass spectrometer, which enhances signal intensities and reduces noise levels, essential for detecting analytes at trace concentrations.

Ionization Techniques, Collision Energy, and Peak Summing

Effective ionization is key to improving sensitivity in mass spectrometry. Choosing the right ionization technique (e.g. electrospray ionization (ESI) for polar analytes or atmospheric pressure chemical ionization (APCI) for less polar compounds) and the correct ionization mode (positive or negative mode) — is crucial for minimizing matrix effects. Collision energy, tailored to the analyte’s structure, optimizes the fragmentation process, further enhancing detection precision.

Peak Summing for Increased Signal: For labs without high-sensitivity instruments, peak summing offers an alternative, where multiple MRM transitions are combined to improve overall signal-to-noise ratio, thus increasing detection sensitivity without noise interference.

Conclusion:

By optimizing each stage of the assay process, Resolian ensures accurate monitoring of low-concentration analytes, supporting the development of life-saving therapies that meet exacting safety and efficacy standards.

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.